Leech Tissue Factor Pathway Inhibitor
Inhibitor of tissue factor / Factor VIIa complex — blocks extrinsic coagulation pathway.
Praeklinisch / mechanistischLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Inhibitor of tissue factor / Factor VIIa complex — blocks extrinsic coagulation pathway.
- Evidence level
- Mechanistic discussion
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
This leech-derived TFPI-like activity is mechanistic only and does NOT establish clinical anticoagulant efficacy. No FDA-approved derivative exists; distinct from human recombinant TFPI products in earlier development.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 32,000 Da
- Source species
- Hirudo medicinalis
Biological Targets
- → tissue factor / Factor VIIa complex
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.